AF3442 

AF3442 is a potent and selective mPGES-1 inhibitor (IC₅₀ = 0.06 μM) which reduces monocyte PGE₂ generation also in the presence of plasma proteins. AF3442 shows selectivity over other prostanoids (TXB₂, PGF_2α and 6-keto-PGF_1α). AF3442 can be used for research in analgesia^[1].

AF3442 (0.01-10 μM, 15 min) causes a concentration-dependent inhibition of PGE₂ generation by human recombinant mPGES-1 with an IC₅₀ of 0.06 μM^[1].
AF3442 (0.01-100 μM, 24 h) causes a concentration-dependent reduction of PGE₂ biosynthesis (IC₅₀ = 0.41 μM), while at 100 μM, the inhibition of PGE₂ was associated with a reduction in TXB₂, suggesting a possible off-target effect on COX-2 activity and expression^[1].
AF3442 (0.01-100 μM, 24 h) significantly reduces COX-2 levels in lipopolysaccharide (LPS) (HY-D1056)-stimulated human monocytes specifically at 100 μM, without affecting COX-1, mPGES-1, mPGES-2, cPGES and TXS levels^[1].
AF3442 (0.01-100 μM, 24 h) is a selective inhibitor of mPGES-1 in LPS-stimulated human whole blood, as evidenced by causing a potent inhibition of PGE₂ by approximately 70% at 100 μM without significantly affecting other prostanoids^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

382.38

C₂₂H₁₇F₃N₂O

924636-93-1

O=C(NC1=CC2=C(C=C1)N(CC)C3=C2C=CC=C3)C4=CC=CC=C4C(F)(F)F

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bruno A, et al. Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. Biochem Pharmacol. 2010 Apr 1;79(7):974-81.  [Content Brief]